BACKGROUND & AIMS: The Ki-RAS oncogene is altered in pancreatic ductal neoplasms. Pancreatic ductal cells (PDCs) were purified from cytokeratin 19 (K19)-Ki-RAS(G12V) transgenic mice and control littermates to identify properties of Ki-Ras activation in a cell-type-specific context. Because Ki-RAS mutation has prognostic significance in patients treated with radiation, we studied the influence of Ki-RAS status on radiation survival. METHODS: Pancreatic ductal fragments from mice with Ki-RAS(G12V) mutation or wild-type (WT)-Ki-RAS were cultured. Growth curves, electron microscopy, flow cytometry, and analysis of signaling and cell-cycle proteins were established. Farnesyltransferase inhibitor (FTI) treatment with R115777 before and after irradiation was used to determine the effect of Ki-Ras farnesylation on cell survival. RESULTS: PDCs from WT and K19-Ki-RAS(G12V) mice had features of ductal cells with formation of 3-dimensional structures on collagen without differences in morphology, growth, and cell-cycle distribution. This may result from up-regulation of p16INK4 and p27(Kip1) and lack of hyperstimulation of the mitogen-activated protein kinase pathway in Ki-RAS(G12V) PDCs. No differences in radiation survival between Ki-RAS(G12V) PDCs and WT PDCs were observed. However, Ki-RAS(G12V) PDCs expressing mutant p53(V143A) had enhanced survival compared with WT PDCs transduced with p53(V143A). R115777 treatment sensitized Ki-RAS(G12V) PDCs and Ki-RAS(G12V)/p53(V143A) PDCs, but not WT PDCs. CONCLUSIONS: Novel characterization of murine WT PDCs and Ki-RAS(G12V) PDCs is described. Induction of cell-cycle regulators and lack of mitogen-activated protein kinase hyperstimulation likely are responsible for constraining activated Ki-RAS(G12V)-mediated proliferation. Because its activation was required for sensitization by an FTI, R115777 may be useful against pancreatic tumors expressing oncogenic Ki-Ras.
BACKGROUND & AIMS: The Ki-RAS oncogene is altered in pancreatic ductal neoplasms. Pancreatic ductal cells (PDCs) were purified from cytokeratin 19 (K19)-Ki-RAS(G12V) transgenic mice and control littermates to identify properties of Ki-Ras activation in a cell-type-specific context. Because Ki-RAS mutation has prognostic significance in patients treated with radiation, we studied the influence of Ki-RAS status on radiation survival. METHODS:Pancreatic ductal fragments from mice with Ki-RAS(G12V) mutation or wild-type (WT)-Ki-RAS were cultured. Growth curves, electron microscopy, flow cytometry, and analysis of signaling and cell-cycle proteins were established. Farnesyltransferase inhibitor (FTI) treatment with R115777 before and after irradiation was used to determine the effect of Ki-Ras farnesylation on cell survival. RESULTS: PDCs from WT and K19-Ki-RAS(G12V) mice had features of ductal cells with formation of 3-dimensional structures on collagen without differences in morphology, growth, and cell-cycle distribution. This may result from up-regulation of p16INK4 and p27(Kip1) and lack of hyperstimulation of the mitogen-activated protein kinase pathway in Ki-RAS(G12V) PDCs. No differences in radiation survival between Ki-RAS(G12V) PDCs and WT PDCs were observed. However, Ki-RAS(G12V) PDCs expressing mutant p53(V143A) had enhanced survival compared with WT PDCs transduced with p53(V143A). R115777 treatment sensitized Ki-RAS(G12V) PDCs and Ki-RAS(G12V)/p53(V143A) PDCs, but not WT PDCs. CONCLUSIONS: Novel characterization of murine WT PDCs and Ki-RAS(G12V) PDCs is described. Induction of cell-cycle regulators and lack of mitogen-activated protein kinase hyperstimulation likely are responsible for constraining activated Ki-RAS(G12V)-mediated proliferation. Because its activation was required for sensitization by an FTI, R115777 may be useful against pancreatic tumors expressing oncogenic Ki-Ras.
Authors: Anchal Chandra; Hernán E Grecco; Venkat Pisupati; David Perera; Liam Cassidy; Ferdinandos Skoulidis; Shehab A Ismail; Christian Hedberg; Michael Hanzal-Bayer; Ashok R Venkitaraman; Alfred Wittinghofer; Philippe I H Bastiaens Journal: Nat Cell Biol Date: 2011-12-18 Impact factor: 28.824
Authors: Johannes von Burstin; Sandra Diersch; Günter Schneider; Maximilian Reichert; Anil K Rustgi; Roland M Schmid Journal: Mol Cancer Res Date: 2015-02-27 Impact factor: 5.852
Authors: Ruben Plentz; Ji-Sun Park; Andrew D Rhim; Daniel Abravanel; Aram F Hezel; Sreenath V Sharma; Sushma Gurumurthy; Vikram Deshpande; Candia Kenific; Jeffrey Settleman; Pradip K Majumder; Ben Z Stanger; Nabeel Bardeesy Journal: Gastroenterology Date: 2009-01-14 Impact factor: 22.682
Authors: Melanie P Wescott; Meritxell Rovira; Maximilian Reichert; Johannes von Burstin; Anna Means; Steven D Leach; Anil K Rustgi Journal: Mol Biol Cell Date: 2009-09-30 Impact factor: 4.138
Authors: Martin C Whittle; Kamel Izeradjene; P Geetha Rani; Libing Feng; Markus A Carlson; Kathleen E DelGiorno; Laura D Wood; Michael Goggins; Ralph H Hruban; Amy E Chang; Philamer Calses; Shelley M Thorsen; Sunil R Hingorani Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Liang Jin; Tao Feng; Hung Ping Shih; Ricardo Zerda; Angela Luo; Jasper Hsu; Alborz Mahdavi; Maike Sander; David A Tirrell; Arthur D Riggs; Hsun Teresa Ku Journal: Proc Natl Acad Sci U S A Date: 2013-02-19 Impact factor: 11.205
Authors: David R Driscoll; Saadia A Karim; Makoto Sano; David M Gay; Wright Jacob; Jun Yu; Yusuke Mizukami; Aarthi Gopinathan; Duncan I Jodrell; T R Jeffry Evans; Nabeel Bardeesy; Michael N Hall; Brian J Quattrochi; David S Klimstra; Simon T Barry; Owen J Sansom; Brian C Lewis; Jennifer P Morton Journal: Cancer Res Date: 2016-10-06 Impact factor: 12.701
Authors: Ulrich Wellner; Jörg Schubert; Ulrike C Burk; Otto Schmalhofer; Feng Zhu; Annika Sonntag; Bettina Waldvogel; Corinne Vannier; Douglas Darling; Axel zur Hausen; Valerie G Brunton; Jennifer Morton; Owen Sansom; Julia Schüler; Marc P Stemmler; Christoph Herzberger; Ulrich Hopt; Tobias Keck; Simone Brabletz; Thomas Brabletz Journal: Nat Cell Biol Date: 2009-11-22 Impact factor: 28.824